 Connection
Kevin Lillehei to Antineoplastic Agents, Alkylating
This is a "connection" page, showing publications Kevin Lillehei has written about Antineoplastic Agents, Alkylating.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.356 |
|
|
|
-
Reddy K, Gaspar LE, Kavanagh BD, Waziri A, Damek DM, Ney D, Lillehei KO, Chen C. Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide. J Neurooncol. 2013 Aug; 114(1):111-6.
Score: 0.107
-
Reddy K, Damek D, Gaspar LE, Ney D, Waziri A, Lillehei K, Stuhr K, Kavanagh BD, Chen C. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2012 Nov 01; 84(3):655-60.
Score: 0.099
-
Chen C, Damek D, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-DeMasters BK, Robischon M, Stuhr K, Rusthoven KE, Kavanagh BD. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):1066-74.
Score: 0.089
-
Kong Q, Kleinschmidt-DeMasters BK, Lillehei KO. Intralesionally implanted cisplatin plus systemic carmustine for the treatment of brain tumor in rats. J Surg Oncol. 1998 Oct; 69(2):76-82.
Score: 0.039
-
Rusthoven KE, Olsen C, Franklin W, Kleinschmidt-DeMasters BK, Kavanagh BD, Gaspar LE, Lillehei K, Waziri A, Damek DM, Chen C. Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series. Int J Radiat Oncol Biol Phys. 2011 Sep 01; 81(1):211-7.
Score: 0.022
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|